未找到相关数据
Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS)
被引：1
作者：
Wu, Y.
Mok, T.
Chu, D.
Han, B.
Liu, X.
Zhang, L.
Zhou, C.
Rukazenkov, Y.
Duffield, E.
Fukuoka, M.
机构：
[1] Guangdong Gen Hosp, Guangzhou, Peoples R China
[2] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China
[3] Canc Hosp, Chinese Acad Med Sci, Beijing, Peoples R China
[4] Shanghai Chest Hosp, Shanghai, Peoples R China
[5] Bejing Canc Hosp, Beijing, Peoples R China
[6] Bejing Union Med Coll Sch, Beijing, Peoples R China
[7] Shanghai Pulm Dis Hosp, Shanghai, Peoples R China
[8] AstraZeneca, Macclesfield, Cheshire, England
[9] Kinki Univ, Sch Med, Osaka 589, Japan
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8041
引用
收藏
页数：3
相关论文